European Psychiatry - Volume 33 - March 2016

274 / 812

S270 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348
EW444
Sexual side effects in patients treated
with desvenlafaxine: An observational
study in daily practice
B. Navarro ∗, L. Perez , L. Erkoreka , A. Arroita , I. Perez
1 Red de Salud Mental de Bizkaia, CSM Barakaldo, Bilbao, Spain
2 Re de Salud Mental de Bizkaia, CSM Barakaldo, Bilbao, Spain
3 Hospital Universitario Cruces, psiquiatría, Barakaldo, Spain
∗ Corresponding author.
Introduction Sexual function is important for patients’ well-being
but it is a common side effect of SSRI and SNRI, included desven-
lafaxine.
Objectives and aims Evaluate incidence and characteristics of sex-
ual dysfunction caused by desvenlafaxine in the clinical practice.
Methods One hundred and thirty-three patients with recently
introduced desvenlafaxine treatment are recruited from Barakldo
and Uribe-Kosta Mental Health Centres in Biscay, Spain. UKU scale
is administered to measure sexual side effects. Statistical analysis
is performed using SPSS v.22.
Results Sexual dysfunction is observed in 5 patients (3.7%) at
50 and 100mg/d (2 and 3 patients, respectively) desvenlafaxine
doses. Two patients (1.5%) have experimented more than one sex-
ual side effect. Regarding gender differences, the most frequent
sexual dysfunctions are diminished sexual desire (5.5%) and erec-
tile dysfunction (5.5%) in men and orgasmic dysfunction (1.2%) in
women (P-values are 0.034; 0.034 and 0.408, respectively). Discon-
tinuation is decided in 60% of patients.
Conclusions Desvenlafaxine has a well-tolerated sexual side
effect profile in general population. There are some gender-related
differences both in presentation and perception, as it has been
described with other drugs, and this should be taken into account
by prescriptors.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW445
The novel antipsychotic cariprazine
(RGH-188): State-of-the-art in the
treatment of psychiatric disorders
L. Orsolini ∗, A. Valchera , D. De Berardis ,
R. Vecchiotti , F. Iasevoli
1 Villa San Giuseppe Hospital, Hermanas Hospitalarias, Department
of Psychiatry, Ascoli Piceno, Italy
2 Maastricht University, Department of Psychiatry and
Neuropsychology, Maastricht, Italy
3 University of Hertfordshire, Department of Pharmacy, School of Life
and Medical Sciences, Hatfield, United Kingdom
4 Polyedra, Polyedra Research, Teramo, Italy
5 Villa San Giuseppe Hospital, Heramanas Hospitalarias, Department
of Psychiatry, Ascoli Piceno, Italy
6 Hospital “G. Mazzini”, ASL 4, NHS, Department of Mental Health,
Psychiatric Service of Diagnosis and Treatment, Teramo, Italy
7 University of “G. D’Annunzio”, Department of Neuroscience,
Imaging and Clinical Science, Chieti, Italy
8 Laboratory of Molecular Psychiatry and
Psychopharmacotherapeutics, Section of Psychiatry, Department of
Neuroscience, University School of Medicine “Federico II”, Naples,
Italy
∗ Corresponding author.
Introduction Cariprazine (RGH-188) is a novel antipsychotic drug
that exerts partial agonismof dopamine D 2/D3 receptors with pref-
erential binding to D3 receptor, antagonism of 5HT2B receptors
and partial agonism of 5HT1A . Currently, cariprazine is in late-
stage clinical development (phase III clinical trials) in patients with
schizophrenia (S) and in patients with bipolar disorder (BD), as
well as an adjunctive treatment in patients with Major Depressive
Disorder (MDD) and drug-resistant MDD.
Objectives Cariprazine has completed phase III trials for the acute
treatment of schizophrenia and bipolar mania, phase II trials for the
bipolar depression and MDD whilst it is undergoing phase III trials
as an adjunct to antidepressants.
Aims The present review aims at proving a comprehensive
summary of the current evidence on the safety, tolerability and
efficacy of cariprazine in the treatment of schizophrenia, BD
(manic/mixed/depressive episode) and MDD.
Methods A systematic search was conducted on PubMed/
Medline/Scopus and the database on Clinical Trials from inception
until April 2015 by typing a set of specified keywords.
Results Available evidence seems to support cariprazine efficacy
in the treatment of cognitive andnegative symptoms of schizophre-
nia. Preliminary findings suggest its antimanic activity whilst it
is still under investigation its efficacy in the treatment of bipolar
depression and MDD. Furthermore, the available data seems not to
allow judgements about its antipsychotic potential in comparison
with currently prescribed antipsychotics.
Conclusions Further studies should be carried out to better inves-
tigate its pharmacodynamic and clinical potential, particularly as
alternative to current antipsychotic drugs.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW446
Use of inhaled loxapine in acute
psychiatric agitation
S. Ovejero ∗, M. Iza , S. Vallejo , C. Vera , A. Sedano ,
R. Álvarez , L. Mata , S. Sánchez-Alonso
1 Hospital Universitario Fundación Jiménez Díaz, Psychiatry, Madrid,
Spain
2 Hospital Universitario Rey Juan Carlos, Psychiatry, Móstoles, Spain
∗ Corresponding author.
Objectives The aimof this work is to study the efficacy of loxapine
inhalation powder on agitated patients in a psychiatric inpatient
unit.
Methods Nineteen patients sample, with an average age of
39.4 years old, diagnosed with schizophrenia, bipolar disorder or
schizoaffective disorder. Patients inhaled loxapine 10mg, using the
staccato system, when they suffered a psychomotor agitation. The
clinical efficacywasmeasured as a change frombaseline in the Posi-
tive and Negative Syndrome Scale-Excited Component (PANSS-EC)
and in the Young Mania Rating Scale (YMRS) one hour after the
administration of loxapine.
Results A mean of 9.8 points reduction (22.6 at baseline and 12.7
one hour after the administration) was found on the PANSS-EC
(t -test, P < .001) and 68.4% of the patients were considered respon-
ders as they obtained a reduction of at least 40% of the basal score.
On 10 of the total of the agitated patients showed an improvement
of the psychomotor excitement, and this allowed the clinicians to
remove the physical restraint; on 6 of the agitated patients the
physical restraint could be avoided during the whole treatment;
and 3 of the patients experienced a reduction of the excitement.
The reduction on PANNS-EC on the latest groupwas not statistically
significant ( t-test, P = .121).
Conclusions Inhaled loxapine was a non-invasive, rapid and
effective alternative treatment for acute agitation in a psychiatric
inpatient unit. It resulted more effective on mild and moderate
cases; not been significantly effective on the severe cases of agi-
tation.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.